Probiotics for Migraine: What a 7-Trial Meta-Analysis Found
A meta-analysis of 7 placebo-controlled trials linked probiotics to about 2 fewer migraine attacks a month, but the evidence was rated very low certainty and no single product was proven.
On this page · 8 sections
Why Probiotics Are Getting Attention
Researchers have been studying the link between the gut and the brain in migraine for years. People with migraine have higher rates of digestive conditions such as irritable bowel syndrome, and several studies have reported differences in gut bacteria between people with and without migraine. That has led to an obvious question: can a probiotic, a supplement that contains live bacteria, help prevent migraine attacks?
Probiotics are easy to buy and widely marketed for general health, so many people with migraine have already tried them. Until recently, the trials were small and scattered. A new meta-analysis in Current Pain and Headache Reports, from researchers at the Children's Hospital of Eastern Ontario and the Scripps Center for Integrative Medicine, pooled the placebo-controlled trials to see what they add up to.
This review complements our recent coverage of a 20-trial network meta-analysis of vitamins and supplements, which did not include probiotics.
How the Review Was Done
The team searched Embase, MEDLINE, and the Cochrane trial register through October 3, 2025, for randomized controlled trials that compared a probiotic with placebo for migraine prevention. Out of 676 screened records, 7 trials met the criteria. One of them was left out of the pooled numbers because participants also received another treatment that was not controlled for, so the pooled results come from 6 trials.
The review looked at three outcomes: pain severity on a 0 to 10 scale, the number of migraine attacks per month, and migraine-related disability. Adult and pediatric trials were also analyzed separately.
The authors rated their evidence with GRADE, a standard system for judging how much confidence a result deserves. "Very low" means the true effect could be substantially different from the estimate. It does not mean probiotics fail. It means the current trials are too few, too small, or too different from one another to give a dependable answer.
What They Found
Each result below is a mean difference compared with placebo. A negative number favors probiotics. When the 95% confidence interval includes zero, the result could be explained by chance.
| Outcome | All Trials | Adults | Children |
|---|---|---|---|
| Attacks per month | 2.06 fewer (95% CI 0.52 to 3.60 fewer) | 2.67 fewer (95% CI 0.93 to 4.41 fewer) | 0.60 more (95% CI 1.98 fewer to 3.19 more), no clear effect |
| Pain severity (0 to 10 scale) | 1.11 points lower (95% CI 2.26 lower to 0.03 higher), not statistically clear | 1.26 points lower (95% CI 2.65 lower to 0.13 higher), not statistically clear | 0.40 points lower (95% CI 0.09 to 0.71 lower) |
| Disability | Standardized mean difference of -0.86 (95% CI -2.33 to 0.60), not statistically clear | Not reported separately | Not reported separately |
Attack frequency was the clearest signal
Across all trials, people taking probiotics had about 2 fewer migraine attacks per month than people taking placebo. The effect came from the adult trials, where the estimate was about 2.7 fewer attacks per month. In the pediatric trials, attack frequency did not improve.
Severity and disability did not reach a clear result
Pain severity trended lower by about 1 point on a 10-point scale, and disability scores also trended better, but both confidence intervals crossed zero. The only clear severity result was in children, and it was small: less than half a point on a 10-point scale.
Adults and children responded differently
A subgroup analysis found that the difference between adult and pediatric results was statistically significant for attack frequency, but not for severity. With only two pediatric trials, it is hard to tell whether this reflects a true age difference or differences between the specific trials.
Reading the Numbers
Two fewer attacks a month would matter to most people with migraine. For context, the supplement network meta-analysis we covered last week found riboflavin 400 mg daily reduced attacks by about 1.95 per month compared with placebo, and that estimate carried moderate certainty. The probiotic estimate is similar in size but rests on much weaker evidence.
The authors name heterogeneity as the main reason for caution. The adult trials varied substantially in their results. Probiotic products also differ in which bacterial strains they contain, how many strains, and at what dose, so a pooled estimate cannot tell you which product, if any, is responsible for the benefit.
Small supplement trials are also vulnerable to the placebo response, which is large in migraine research. Our article on placebo response in migraine trials explains why small effects in small studies often shrink when larger trials are run. A similar pattern played out with ginger, where our review of the ginger evidence found low or very low certainty despite several positive trials.
What This Means If You Are Considering Probiotics
Probiotics are not a replacement for an established preventive. If you have frequent attacks, the options with the strongest evidence are summarized in our article on the AAN and AHS migraine prevention guideline. For other supplements and herbal products, see our evidence-based guide to migraine nutraceuticals.
- No specific probiotic product or strain has been shown to prevent migraine attacks. This review pooled different products.
- If you decide to try one, change one thing at a time and keep a headache diary so you can tell whether it helps.
- Give it about three months, and use the preventive response calculator to compare your migraine days before and after.
- Keep taking any preventive your clinician prescribed unless you have discussed a change with them.
- People with a weakened immune system, a central venous catheter, or a serious illness should ask their physician before taking probiotics.
- For children, the pediatric trials did not show fewer attacks, so talk with your child's pediatrician before using probiotics for migraine.
Limitations
- Only 7 trials and 612 participants were included, and the pooled analysis drew on 6 of those trials.
- The evidence was rated very low certainty, mainly because the trials differed from one another.
- The trials used different probiotic products and doses, so the result cannot be tied to one product.
- Only two trials were in children, which limits any conclusion about pediatric use.
- The literature search ended in October 2025, so trials published after that date were not included.
Key Takeaways
- Across 7 placebo-controlled trials, probiotics were linked to about 2 fewer migraine attacks per month, driven by the adult trials.
- Effects on pain severity and disability were not statistically clear.
- The pediatric trials did not show fewer attacks.
- The certainty of the evidence was very low, and no single product has been proven to work.
- Larger trials that test specific strains at set doses are needed.
If you plan to bring this up at your next visit, our printable migraine appointment summary sheet helps you list the supplements and medicines you have tried along with your monthly migraine days.
This article is for educational purposes only and does not replace medical advice, diagnosis, or treatment. Talk with your doctor before starting, stopping, or changing any treatment, including probiotics and other supplements.
References
- Gasner N, Sweeney M, Piché JV, et al. Effects of probiotics on migraine in children and adults: a systematic review and meta-analysis. Current Pain and Headache Reports. 2026;30(1):139. doi:10.1007/s11916-026-01576-3.
- Ahmed M, Aiman U, Kukreja N, et al. Comparative efficacy of vitamins and nutraceuticals for migraine prevention: a systematic review and network meta-analysis of randomized controlled trials. Headache: The Journal of Head and Face Pain. 2026. doi:10.1111/head.70268.





